Background
Lung cancer screening programs may provide opportunities to reduce smoking rates among participants. This study evaluates the impact of lung cancer screening results on smoking cessation.
Methods
Data from Lung Screening Study participants in the National Lung Screening Trial (NLST; 2002-2009) were used to prepare multivariable longitudinal regression models predicting annual smoking cessation in those who were current smokers at study entry (n = 15 489, excluding those developing lung cancer in follow-up). The associations of lung cancer screening results on smoking cessation over the trial period were analyzed. All hypothesis testing used two sided P values.
Results
In adjusted analyses, smoking cessation was strongly associated with the amount of abnormality observed in the previous year's screening (P < .0001). Compared with those with a normal screen, individuals were less likely to be smokers if their previous year's screen had a major abnormality that was not suspicious for lung cancer (odds ratio [OR] = 0.811; 95% confidence interval [CI] = 0.722 to 0.912; P < .001), was suspicious for lung cancer but stable from previous screens (OR = 0.785; 95% CI = 0.706 to 0.872; P < .001), or was suspicious for lung cancer and was new or changed from the previous screen (OR = 0.663; 95% CI = 0.607 to 0.724; P < .001). Differences in smoking prevalence were present up to 5 years after the last screen.
Conclusions
Smoking cessation is statistically significantly associated with screen-detected abnormality. Integration of effective smoking cessation programs within screening programs should lead to further reduction in smoking-related morbidity and mortality.
The US National Lung Screening Trial (NLST) demonstrated that annual low-dose computed tomography (LDCT) lung cancer screening reduces lung cancer mortality by 20% compared with chest x-ray (CXR) screening (1) . Consequently, several organizations, as well as the United States Preventive Services Task Force (2) , have recommended lung cancer screening of high-risk individuals (3) (4) (5) (6) (7) . Although lung cancer screening itself confers benefit through early detection and treatment, screening and screening results (whether related to lung cancer or other non-lung cancer diagnoses), may provide a "teachable moment" that encourages smoking cessation (8) (9) (10) (11) (12) (13) (14) (15) (16) . If this is the case, then lung cancer screening may have the potential to reduce morbidity and mortality through multiple mechanisms. The four major causes of mortality in developed countries-cancer, cardiovascular disease, stroke, and respiratory disease-are linked to smoking, and risks for these diseases decline after smoking cessation (17, 18) . Advancing smoking cessation is a public health priority.
Past studies have investigated smoking behavior in lung cancer screening trials (14) (15) (16) 19) and in one screening program (13) . Most of them have investigated the impact of screening vs no screening on smoking behavior (14, 15, 19) or, in screened individuals, the impact of an abnormal vs a normal screen (13) (14) (15) (16) 19) , with all abnormalities pooled. Several other studies have been relatively small, have only looked at short-term effects, or have only included a single screen on the next smoking evaluation (9, 10, 12) , with two exceptions (11, 13) . The long-term impacts of specific graded screening results on smoking cessation have not been assessed.
Our study aim was to evaluate the impact of lung cancer screening results on smoking cessation over time, with screening results measured in several refined categories. We evaluated the associations between screening results and subsequent smoking behavior in baseline current smokers, adjusted for important factors. up and were excluded from analysis because their disease may have influenced their smoking behavior. Of the remaining 15 489 individuals, complete epidemiologic data for multivariable modeling were available for 14 621 (94.4%). We evaluated whether annual selfreported smoking behavior was associated with preceding screening results, adjusted for important factors. The LSS annual summary update questionnaire initially asked the question, "Did you smoke 20 cigarettes in the last 30 days?" On July 1, 2004, to attempt to better harmonize with ACRIN, the question was changed to "Have you smoked any cigarettes, even a puff, in the last seven days?" In the current analysis, we consider an individual to be a current smoker if they answered yes to either question. The transition from the first to second question was almost complete by T3 and is presented by study year in Supplementary Table 1 (available online) .
Our primary predictor of interest was screening result, which was classified by study radiologists as one of the following: 1) normal, no abnormalities; 2) negative for lung cancer, minor other abnormality observed: LDCT, morphologically benign nodules or noncalcified nodules less than 4 mm; CXR, nodules containing benign patterns of calcification; 3) negative for lung cancer, clinically significant other abnormality observed: any finding requiring clinical follow-up (eg, chronic obstructive pulmonary disease); 4) positive (suspicious) for lung cancer: LDCT, noncalcified nodule measuring 4 mm or greater in any diameter; CXR, any noncalcified nodule or mass and adenopathy or effusion.
Screening results data collection forms were consistent between CXR and LDCT study arms. The study protocol did not advocate specific smoking cessation programs except to offer literature (Clear Horizons) to current smokers. Each site could elect to provide additional information, such as phone hotlines. No LSS sites provided active organized smoking cessation programs or involvement in randomized controlled trials of cessation.
Statistical Methods
Descriptive statistics overall and stratified by smoking status at study year 3 (T3) were carried out with contingency table analyses and χ 2 tests for categorical variables and t tests with unequal variances for continuous variables. T3 was selected as a relevant outcome point because it is the first time point when smoking behavior was reported after completion of the final screening at T2, given that we lagged the association of screening on smoking cessation by 1 year.
Generalized estimating equations with unstructured correlation and robust standard errors were used to prepare logistic regression models for longitudinal data. This method takes into account clustering of data within individuals due to repeated measures. In addition, we prepared longitudinal logistic regression random effects models. Both approaches led to identical conclusions. The generalized estimating equations results are more conservative and are presented here.
Covariables considered in models were those thought to be associated with smoking behavior a priori based on our previous research (19) , expert opinion, and prior literature. Such covariables included sociodemographic factors (age, sex, race/ethnicity, education as an estimator of socioeconomic circumstance, and marital status), exposures (alcohol consumption, cigarette, cigar and pipe smoking histories, and secondhand smoke exposures), and medical history (body mass index [BMI] , family history of lung cancer, personal history of cancer, history of comorbidities). We did not have data on biologic markers of smoking behavior and nicotine dependence. All models were adjusted for study year, randomization arm, and study center.
Nonlinear associations between continuous variables and the study outcome were assessed in models using restricted cubic splines (22) . Four knots were used to describe three splines. Knot locations were based on percentile distribution of the data as described by Harrell (22) to ensure adequate coverage. Selected interactions of variables in the final model were evaluated. None were statistically significant, and they are not discussed further. We evaluated whether our final model and study conclusions differed by how the smoking status question was asked in the annual summary update by including these variables in the model and by stratifying on levels of these variables.
Statistics were produced using Stata MP 12.1 (StataCorp, College Station, TX). Hypothesis testing used two-sided tests with alpha error at less than .05.
results

Study Population
The study population stratified by smoking status at T3 and overall is described in Table 1 . Study participants were an average age of 60.6 years and were 58.7% male and 89.5% white. Table 2 presents Table 1 . Distribution of study variables in National Lung Screening Trial Lung Screening Study current smokers who were not diagnosed with lung cancer in study follow-up, overall and stratified by smoking status at study year 3 (T3)* * HS = high school; SD = standard deviation. † Row percentages are presented to allow easy calculation of smoking prevalence ratios comparing different levels of exposure. ‡ The P value comparing smokers to nonsmokers at T3 for categorical data is by χ 2 test and for continuous variables is by t test with unequal variances. All tests were two-sided. § Alcohol score is the average number of drinks consumed when drinking times the average number of times per month that alcohol was consumed. * T0 to T7 refer to the study year after baseline. Three annual screenings were carried out starting with baseline (T0) and at one (T1) and two (T2) years later. T3 to T7 refer to the annual summary updates for the National Lung Screening Trial cohort occurring at 3, 4, 5, 6, and 7 years. † Odds ratios (ORs) (95% confidence intervals) are for smoking for each follow-up period compared with normal screen as the referent group. Individuals who developed lung cancer in the follow-up period are excluded.
Variables
the cumulative cross-sectional proportions of participants who were smoking at follow-up stratified by screening results. At T0, T1, and T2 screenings, 36.8 % ( Table 2 , example 5403/14 692), 33.9%, and 32.2% of screens were normal, respectively. Similarly, a positive (suspicious for lung cancer) result (new, unstable or stable) was received by 18.6%, 18.1%, and 10.8%, respectively, and 7.2%, 3.8%, and 3.7% were negative (not suspicious) for lung cancer but had another clinically significant abnormality found. Table 2 and Figure 1 show the proportion of baseline current smokers who were smokers in subsequent years stratified by their preceding screening result. In almost all years for each screening result strata, smoking declined over time. Generally, for each study year, the relative relationship between screening result and smoking remained constant. The one exception occurred in individuals who had a T2 screen that had a major abnormality not suspicious for lung cancer. In this group, at T7, a slight increase occurred in smoking prevalence compared with at T6. This was the smallest subgroup and was vulnerable to response fluctuations. T7 occurred at the end of the trial, and a large decline in the cohort size occurred from T6 to T7 (16.1%).
Screening Results and Subsequent Smoking
The highest proportion of smoking occurred in those with a normal screen. The second highest proportion occurred in those who had a screen that had a minor abnormality not suspicious for lung cancer. An even lower fraction of smoking was observed in those whose screen had a major abnormality not suspicious for lung cancer. The smoking proportions in individuals who had screens that were suspicious for lung cancer but that were stable, unchanged from the previous screen, were similar to individuals with screens that had a major abnormality not suspicious for lung cancer. The lowest rate of smoking was observed in those who had a screen that was suspicious for lung cancer, which was a new or changing abnormality.
The cumulative impact of screening results on smoking prevalence appeared to be durable. Five years after the last screening (T7), a statistically significant difference was still observed between the different screening results (Figure 1 ; Table 2 ). For example, the proportion smoking at T7 in those who had T2 screens that were normal was 0.618 and in those who had screens that had an abnormality suspicious for lung cancer, stable or unstable, was 0.575 (odds ratio [OR] = 0.836; 95% confidence interval [CI] = 0.729 to 0.960).
Multivariable Longitudinal Logistic Regression Model Predicting Smoking
Our final multivariable logistic model of continued smoking in baseline current smokers (Table 3) found that increased risk of continued smoking was associated with younger age, lower education, being spouseless, lower BMI, history of heavier smoking intensity (cigarettes smoked per day), longer smoking duration, exposure to secondhand smoke at home, and no history of regular pipe or cigar smoking. BMI had a nonlinear relationship with subsequent smoking (P nonlinearity = .004).
In multivariable analysis (Table 3) , continued smoking was statistically significantly associated with screening result from the previous year (P < .0001). Compared with having a normal screen, the odds ratio for continuing smoking between T1 and T3 for individuals with screens that had a minor abnormality that was not suspicious for lung cancer was 0.914 (95% CI = 0.859 to 0.974; P = .005); for individuals with screens that had a major abnormality that was not suspicious for lung cancer, the odds ratio was 0.811 (95% CI = 0.722 to 0.912; P < .001); for individuals with screens that were suspicious for lung cancer but were stable from the previous screen, the odds ratio was 0.785 (95% CI = 0.706 to 0.872; P < .001); and for individuals with screens that were suspicious for lung cancer that were new or unstable, the odds ratio was 0.663 (95% CI = 0.607 to 0.724; P < .001). The likelihood of continued smoking was inversely associated with severity of screening results.
Sex, Hispanic ethnicity, comorbidities and intervention arm were evaluated in the multivariable model, and all had P values greater than .15 and had no important impact on estimates for the cessation outcome. Table 4 shows the adjusted odds ratios for screening result and continued smoking, stratified by intervention arm. Generally, the associations are present in both groups. The only exception occurs in those who were in the LDCT arm who had a minor abnormality not suspicious for lung cancer; they had no decline in smoking relative to those with a normal result.
During the course of the NLST, the annual LSS question that inquired about current smoking changed. In analysis we treated the two questions as if they equivalently measured current smoking status. We assessed whether the version of smoking question impacted the final model. In multivariable logistic modeling, the question version was not associated with the study outcome (OR = 1.046; 95% CI = 0.971 to 1.126; P = .23), and our study estimates for screen results did not change substantially. When the final model was stratified on smoking question version, the associations between screening results and smoking remained similar to those presented in Table 3 . Version of study question did not impact findings.
Discussion
Our study found many factors to be associated with continued smoking in the lung cancer screening setting. Our current NLST LSS findings agree with our recent Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial findings that continued smoking is associated with younger age, lower socioeconomic circumstance, being spouseless, lower BMI, smoking intensity and duration, and secondhand smoke exposure (19) . Our findings are consistent with those observed in other studies (11, 13, 14) .
Our study demonstrates that in adjusted analysis, screening result is an important and statistically significant predictor of subsequent smoking and that smoking was inversely associated with severity of the screening result. These associations, for the most part, held whether the screening was by CXR or LDCT. These strong consistent associations have not been described previously. It has been speculated that individuals whose screens are normal Table 2 . Proportion smoking at year 1 was classified by the baseline screening result, proportion smoking at year 2 was classified by year 1 screening result, proportion smoking at years 3 through 7 were classified by the last screen result, which occurred in study year 2. LCa, lung cancer; NotLCa, not suspicious for lung cancer.
continue their unhealthy behaviors because they think they have a clean bill of health-the health-certificate effect. Although our findings do not present proof dispelling the health-certificate effect, our findings suggest that they were not a major problem, because those with normal screens had sharply declining prevalences of smoking over time that paralleled those observed in participants with abnormalities.
Although studies have investigated lung cancer screening and smoking behavior, none have looked at smoking cessation and screening results in detail. Styn and colleagues (2009) found that computed tomography (CT) screening results that led to abnormal results and a physician referral were associated with increased likelihood of smoking cessation 1 year later (23) . Their study did not have repeated measurements or long follow-ups and had a simple summary measure of screening result. Townsend et al. (2005) evaluated the impact of three annual lung cancer screenings using CT (11) . They used longitudinal analysis and found that an abnormal screening result was associated with smoking cessation. In the Early Lung Cancer Action Program (ELCAP) (13) , an abnormal screening result was associated with a higher rate of point abstinence compared with those with normal results. This difference occurred primarily during the early screens, when the positive screening results were most likely to occur, and suggests that the impact of a positive screening result might be short-lived. Our much larger study included a richer assortment of covariables in modeling and used a refined multilevel measure of screening results and was able to evaluate a dose-response relationship. Failure of some studies to find an association between screening results and smoking cessation is likely because of misclassification or poor classification of screen results, lack of lagging predictor in analysis, and limited study power. In summary, our study agrees with some past studies and extends the relationship between screening result and smoking cessation.
Our study does have limitations. Our analysis summarized overall smoking cessation behavior but did not evaluate changing patterns of cessation-relapse. Such an analysis was not practical because the number of permutations is large (ie, 128).
Current smoking status was determined by self-report and was not biologically validated. This is not expected to lead to great misclassification and has been the assessment method in most lung cancer screening studies (10, 11, 13, 15, 16) . Studts and colleagues conducted a validation study of self-reported smoking status among participants in a lung screening trial using urine cotinine as the gold standard (24) . Excluding nicotine patch users, the kappa statistic for agreement was 0.96 (95% CI = 0.88 to 1.00), indicating excellent agreement. Table 3 . Multivariable generalized estimating equation logistic regression model* for current smoking status (yes vs no) at study years 1, 2, and 3 after baseline for baseline current smokers (n = 14 621)
Predictor variables
Odds ratio (95% CI) P The LSS annual summary update question asking about current smoking status changed during the course of follow-up. However, the study findings were consistent and statistically significant when the analysis was limited to one or the other question. Furthermore, the Pan-Canadian Early Detection of Lung Cancer Study of 2537 smokers asked both of these questions and found 96.7% and 96.2% agreement between them at years 1 and 2, indicating consistency between measures (25) .
The LSS did not measure some potential confounders, such as nicotine dependence. However, we did include smoking intensity, a strong correlate of nicotine dependence, in multivariable models. Furthermore, it is unlikely that nicotine dependence or other potential confounders would lead to such a highly statistically significant consistent dose-response association (P < .0001).
Our study has several strengths. The NLST is a large, prospective study with repeated measures of smoking behavior and careful systematic classification of screening outcomes. In addition, it had a high percentage of women (41%), more than 10% of individuals from minority groups, and retention of 73% over 7 years. Our longitudinal data analysis made efficient use of data and provided interpretable summary statistics.
Our findings suggest that in the lung cancer screening setting, abnormal screening results may present a "teachable moment." On average, those with abnormal results suspicious for lung cancer reported approximately 6% lower rate of smoking compared with those with normal results. This represents a clinically relevant difference. Proven smoking cessation programs applied to such receptive individuals might further increase smoking cessation. Our findings strongly indicate that smoking cessation programs be incorporated into lung cancer screening programs.
Our findings need to be validated in other high-quality prospective studies in different populations. Future cost-effectiveness analyses and microsimulation models evaluating various lung cancer screening scenarios should take into account that abnormal lung screens are common in high-risk individuals and they are associated with increased rates of smoking cessation, which generally reduce morbidity and mortality and extend life expectancy.
Our study found that lung cancer screening results statistically significantly impact subsequent smoking behavior and may present a "teachable moment" for smoking cessation interventions. Future lung cancer screening programs should take advantage of this opportunity to apply effective smoking cessation programs. , family history of lung cancer, smoking intensity and duration, exposure to secondhand smoke in the home, regular pipe or cigar smoking, study year, and study center as described in Table 3 . Smoking status data were for years 1, 2, and 3 after baseline. The screening results were lagged to 1 year before smoking status and came from baseline and years 1 and 2 after baseline, respectively. Individuals who developed lung cancer in the follow-up period were excluded from analysis. CI = confidence interval.
